Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Accured Expenses (2016 - 2026)

Iradimed has reported Change in Accured Expenses over the past 14 years, most recently at -$1.2 million for Q1 2026.

  • Quarterly Change in Accured Expenses rose 23.46% to -$1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $203000.0 through Mar 2026, up 120.84% year-over-year, with the annual reading at -$150000.0 for FY2025, 50.0% down from the prior year.
  • Change in Accured Expenses was -$1.2 million for Q1 2026 at Iradimed, down from -$449420.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $943389.0 in Q2 2025 and troughed at -$1.5 million in Q1 2025.
  • The 5-year median for Change in Accured Expenses is -$7994.0 (2022), against an average of -$96097.1.
  • The largest YoY upside for Change in Accured Expenses was 3227.35% in 2023 against a maximum downside of 618.85% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $66838.0 in 2022, then tumbled by 618.85% to -$346787.0 in 2023, then plummeted by 75.65% to -$609123.0 in 2024, then rose by 26.22% to -$449420.0 in 2025, then plummeted by 156.33% to -$1.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Change in Accured Expenses are -$1.2 million (Q1 2026), -$449420.0 (Q4 2025), and $861031.0 (Q3 2025).